文章摘要

胃癌组织中CEACAM6的检测及其与T细胞的相互作用

作者: 1黄霞, 1崔晶娴, 1陈烨, 1葛仁美
1 南通大学附属海安医院检验科,江苏 海安 226681
通讯: 黄霞 Email: hujsyy189000@163.com
DOI: 10.3978/j.issn.2095-6959.2018.11.017

摘要

目的:探讨胃癌组织中CEACAM6的检测及其与T细胞的相互作用。方法:选择2012年6月至2015年4月在南通大学附属海安医院手术切除并经病理证实为原发性胃癌患者标本90例进行研究,患者术前均未接受放化疗或免疫治疗。采用免疫组织化学法检测90例患者胃癌组织中的CD3,CD4,CD8,CD45R0与CEACAM6的表达。结果:CD3,CD8与CD45R0 T细胞阳性浸润密度与TNM分期、分化程度和转移情况有关,在TNM I期、II期,高分化、淋巴转移的患者中有较高表达(P<0.05),与性别、年龄、病理形态学、病变部位无关(P>0.05)。CEACAM6的表达单因素与多因素结果均显示与TNM分期和淋巴转移有关,在TNM III期、IV期、淋巴转移的患者中有较高表达(P<0.05),与性别、年龄、病理形态学、病变部位、分化程度无关(P>0.05)。CEACAM6强阳性表达率为61.11%(55/90),CEACAM6的高表达与CD8+ T细胞和CD45R0呈负相关(P<0.05),而与CD3+ T细胞和CD4+ T细胞无关(P>0.05)。不同强度CD4的表达者生存时间差异无统计学意义(P>0.05)。CD3,CD8和CD45R0强阳性表达者生存时间更长,中位生存时间分别为24,26,29个月(P<0.05)。CEACAM6弱阳性与阴性表达者生存时间更长,中位生存时间为29个月(P<0.05)。结论:CEACAM6与胃癌的恶性程度和有无淋巴转移相关,其表达对胃癌中肿瘤浸润的T细胞具有抑制作用。
关键词: 胃癌;CEACAM6;T细胞;预后

Detection of CEACAM6 in gastric carcinoma tissue and its interaction with T cells

Authors: 1HUANG Xia, 1CUI Jingxian, 1CHEN Ye, 1GE Renmei
1 Department of Laboratory, Hai’an Hospital, Affiliated to Nantong University, Hai’an Jiangsu 226681, China

CorrespondingAuthor: HUANG Xia Email: hujsyy189000@163.com

Abstract

Objective: To investigate the detection of CEACAM6 in gastric cancer and its interaction with T cells. Methods: A total of 90 patients with primary gastric cancer who underwent surgical resection from June 2012 to April 2015 in Hai’an Hospital Affiliated to Nantong University were enrolled. None of the patients received radiotherapy and chemotherapy or immunotherapy before surgery. Immunohistochemistry was used to detect the expression of CD3, CD4, CD8, CD45R0 and CEACAM6 in gastric cancer tissues of 90 patients. Results: The positive infiltration density of CD3, CD8 and CD45R0 T cells was closely related to TNM staging, differentiation and metastasis. In TNM stage I and stage II, patients with high differentiation and lymphatic metastasis were highly expressed (P<0.05). It was not related to gender, age, pathological morphology, and lesion location (P>0.05). The single-factor and multi-factor results of CEACAM6 expression were closely related to TNM stage and lymphatic metastasis, high expression in patients with stage III, IV, and lymphatic metastasis of TNM (P<0.05). It was not related to gender, age, pathological morphology, lesion location, and degree of differentiation (P>0.05). The strong positive rate of CEACAM6 was 61.11% (55/90). The high expression of CEACAM6 was negatively correlated with CD8+ T cells and CD45R0 (P<0.05), but not with CD3+ T cells and CD4+ T cells (P>0.05). There was no significant difference in survival time between different intensity of CD4 expression (P>0.05). Patients with strong positive expression of CD3, CD8 and CD45R0 had longer survival time and median survival time of 24, 26 and 29 months (P<0.05). The weak positive and negative expression of CEACAM6 had longer survival time and the median survival time was 29 months (P<0.05). Conclusion: CEACAM6 is associated with the degree of malignancy and lymphatic metastasis of gastric cancer. The expression of CEACAM6 has an inhibitory effect on tumor infiltrating T cells in gastric cancer.
Keywords: gastric cancer; CEACAM6; T cell; prognosis